Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J)

Autor:	Nobuyuki Katakami, Seiji Yano, Katsuhiko Nagase, M. Ando, Tetsuo Hase, Akito Hata, Tsuyoshi Takahashi, Shinobu Shimizu, Yoshinori Hasegawa, Shinji Takeuchi, Tadami Fujiwara, Kenichi Yoshimura, Hirotsugu Kenmotsu
Rok vydání:	2017
Předmět:	Gefitinib Oncology business.industry Mutant medicine Cancer research Combined therapy Hematology Lung cancer medicine.disease business Vorinostat medicine.drug
Zdroj:	Annals of Oncology. 28:x137-x138
ISSN:	0923-7534
DOI:	10.1093/annonc/mdx671.036
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::66f4225d7ef4bfc286a9dbd33d95e5ef https://doi.org/10.1093/annonc/mdx671.036 Zobrazit plný text záznamu